Aquilo Capital Management, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Aquilo Capital Management, LLC reported 12 stock positions worth $37.1 million. Its top holding was Blueprint Medicines (BPMC) at 20.0% of the portfolio, followed by Arrowhead Pharmaceuticals (ARWR, 18.9%) and Protagonist Therapeutics (PTGX, 10.7%). Compared with Q4 2024, it opened 1 new position, sold out of 2, added to 3 and reduced 7. The biggest buy was Precision Biosciences (DTIL, shares +35%) and the biggest sale an exit from Silence Therapeutics PLC-ADR (SLN).
- Most Recent 13F
- Q3 2025
- Location
- SAN FRANCISCO, CA
- CIK
- 0001591986
- Portfolio Value
- $37.1M (Q1 2025)
- SEC Filing
- 0001591986-25-000004 ↗ filed May 15, 2025
Holdings Value
Holdings 12 stocks · $37.1M
| BPMC Blueprint Medicines Corp. | 20.03% | 83,926 | $7.4M | Reduce -35.2% |
| ARWR Arrowhead Pharmaceuticals Inc. | 18.90% | 550,130 | $7.0M | Reduce -22.3% |
| PTGX Protagonist Therapeutics Inc. | 10.65% | 81,692 | $4.0M | Add +6.7% |
| KYMR Kymera Therapeutics Inc. | 10.22% | 138,521 | $3.8M | Reduce -24.5% |
| DTIL Precision Biosciences Inc. | 9.34% | 726,149 | $3.5M | Add +35.4% |
| ARVN Arvinas Inc. | 6.83% | 360,766 | $2.5M | Add +9.7% |
| RGNX Regenxbio Inc. | 5.23% | 271,302 | $1.9M | Reduce -21.7% |
| ACET Adicet Bio Inc. | 5.00% | 2,456,194 | $1.9M | Reduce -3.0% |
| BCYC Bicycle Therapeutics PLC-ADR | 3.93% | 171,695 | $1.5M | Reduce -22.6% |
| IMTX Immatics NV | 3.71% | 304,902 | $1.4M | Reduce -18.4% |
| RPTX Repare Therapeutics Inc. | 3.44% | 1,293,715 | $1.3M | No change |
| ZYME Zymeworks Inc. | 2.71% | 84,482 | $1.0M | New |
Options reported separately and not counted above: AMGN calls ($18.7M).
Portfolio Sells Q4 2024 → Q1 2025
| SLN Silence Therapeutics PLC-ADR | Sold out | 0.00% | −4.33 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -22.3% | 18.90% | −3.88 |
| KYMR Kymera Therapeutics Inc. | Reduce -24.5% | 10.22% | −2.42 |
| BCYC Bicycle Therapeutics PLC-ADR | Reduce -22.6% | 3.93% | −1.39 |
| IMTX Immatics NV | Reduce -18.4% | 3.71% | −0.84 |
| STRO Sutro Biopharma Inc. Com SHS | Sold out | 0.00% | −0.00 |
| RGNX Regenxbio Inc. | Reduce -21.7% | 5.23% | +0.65 |
| BPMC Blueprint Medicines Corp. | Reduce -35.2% | 20.03% | +0.67 |
| ACET Adicet Bio Inc. | Reduce -3.0% | 5.00% | +0.83 |
Portfolio Buys Q4 2024 → Q1 2025
Options Activity Q4 2024 → Q1 2025
| AMGN Amgen Inc. | call | Add +140.0% | 60,000 | $18.7M |
| ARWR Arrowhead Pharmaceuticals Inc. | call | Sold out | 75,000 | $1.4Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.